Med-Bio Analyst Upgrades & Downgrades (BMY, EHTH, IMCL, BABY, NUVA, ONXX, OSIP, ZMH)
These are some of the analyst calls that have been seen in medical and biotech this Friday morning:
- Bristol-Myers (NYSE: BMY) raised to Outperform at Bernstein.
- EHealth (NASDAQ: EHTH) Raised to Overweight at Thomas Weisel.
- ImClone Systems (NASDAQ: IMCL) Started as Overweight at Thomas Weisel.
- Natus Medical (NASDAQ: BABY) Started as Buy at UBS.
- NuVasive (NASDAQ:: NUVA) Raised to Overweight at Thomas Weisel.
- Onyx Pharmaceuticals (NASDAQ: ONXX) Started as Market Weight at Thomas Weisel.
- OSI Pharmaceuticals (NASDAQ: OSIP) Started as Overweight at Thomas Weisel.
- Zimmer (NYSE: ZMH) Downgraded to Market Weight from Overweight at Thomas Weisel.
Jon C. Ogg
June 27, 2008
BioHealth & Medical Analyst Calls (AZN, NVS, NVO, CRL, IVGN, APPY, TWTI)
BNP Paribas overseas has lowered ratings of AstraZeneca (NYSE: AZN) to Underperform from Neutral; and raised Novartis (NYSE: NVS) to Neutral from Underperform.
Goldman Sachs has raised Novo Nordisk (NYSE: NVO) to Buy from Neutral; Charles River Laboratories (NYSE: CRL) downgraded to Neutral at Goldman Sachs.
JPMorgan has raised its rating on Invitrogen (NASDAQ: IVGN) to Overweight from Neutral.
Lazard Capital Markets started coverage of Aspenbio (NASDAQ: APPY) with a “Buy” rating.
R.W.Baird Downgraded Third Wave Technologies (NASDAQ: TWTI) to Neutral from Outperform.
Jon Ogg
June 24, 2008
Positive Biotech Analyst Calls (AMGN, ATHX, DNA, GILD, SEPR)
These are some of the upgrades and positive calls already being seen in the biotech sector this Thursday morning:
- Amgen (NASDAQ: AMGN) Started as Buy at Deutsche Bank.
- Athersys (NASDAQ: ATHX) started as Buy at Lazard Capital.
- Genentech (NYSE: DNA) Started as Buy By Deutsche Bank.
- Gilead (NASDAQ: GILD) Started as Buy at Deutsche Bank.
- Sepracor (NASDAQ: SEPR) raised to Buy at UBS.
You can see the list of negative calls and downgrades here.
Jon Ogg
June 19, 2008
BioHealth Analyst Cautious/Negative Calls (BIIB, ESRX, GENZ, MHS, SGEN)
These are some of the downgrades and negative or cautious calls being seen in the biotech and medical-health sectors this Thursday morning:
- Biogen-IDEC (NASDAQ: BIIB) Started as Hold at Deutsche Bank.
- Express Scripts (NASDAQ: ESRX) Cut to Neutral from Buy at UBS.
- Genzyme (NASDAQ: GENZ) Started As Hold at Deutsche Bank.
- Medco Health Solutions (NYSE: MHS) cut to Neutral at UBS.
- Seattle Genetics (NASDAQ: SGEN) Started as Neutral at UBS.
You can see the list of positive calls and upgrades here.
Jon Ogg
June 19, 2008